Conjugates and uses thereof

A GD2-targeting antigen binding protein conjugate addresses the limitations of current osteosarcoma treatments by enhancing treatment efficacy and survival rates through targeted cytotoxicity against osteosarcoma cells.

WO2026123077A1 Publication Date: 2026-06-18THE UNIV OF SYDNEY +2
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
THE UNIV OF SYDNEY
Filing Date
2025-12-12
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current treatments for osteosarcoma, including surgery, chemotherapy, and radiotherapy, have a 5-year survival rate of only 60-70% for localized disease and drop to 20% for metastatic cases, highlighting the need for new medications and approaches.

⚗Method used

Development of a conjugate comprising an antigen binding protein targeting the GD2 antigen, conjugated to a cytotoxic agent, specifically designed to enhance treatment efficacy against osteosarcoma.

🎯Benefits of technology

The conjugate effectively targets GD2-expressing osteosarcoma cells, increasing treatment efficacy and survival rates by inducing apoptosis and reducing metastasis, as demonstrated in preclinical models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to anti-GD2 antibody-drug conjugates, compositions comprising the same and uses thereof in the treatment of osteosarcoma.
Need to check novelty before this filing date? Find Prior Art